
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst Inc has demonstrated a consistent increase in earnings power over the past seven years, evidenced by rising EBITDA, a growing client base, and a reduction in headcount. The company benefits from positive trends in the healthcare market, as hospital executives report volumes exceeding budget expectations, which correlates with heightened demand for Health Catalyst's technology solutions. As the acute care market continues to recover from inflationary pressures and labor constraints, the outlook for revenue growth and improved margins appears favorable, further supporting a positive perspective on the company's financial trajectory.
Bears say
Health Catalyst Inc. has experienced a slowdown in total revenue growth, compounded by a highly penetrated total addressable market (TAM) among health systems, raising concerns regarding potential revenue and EBITDA decline in the coming years. The company's guidance for both 2025 and 2026 indicates a negative trend, with lower year-over-year revenue projections and a decrease in net dollar-based retention, suggesting challenges in maintaining existing client contracts. Additionally, pressures on margins, headwinds from Medicaid funding, and a changing hospital buying environment create further uncertainty for the company's financial outlook.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares